靶向新生可溶性Aβ42用于潜在的阿尔茨海默病药物研发。 - Suppr

Suppr

超能文献

Targeting nascent soluble Aβ42 for potential Alzheimer drug development.

作者信息

Zhang Mingming, Hausmann Laura, Song Weihong

出版信息

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.

DOI:10.1111/jnc.12156

PMID:23405973

Abstract

摘要

相似文献

Targeting nascent soluble Aβ42 for potential Alzheimer drug development.

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.

Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.

J Neurochem. 2013 May;125(3):465-72. doi: 10.1111/jnc.12125. Epub 2013 Jan 8.

Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

J Alzheimers Dis. 2010;22(2):401-4. doi: 10.3233/JAD-2010-101548.

Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.

J Neurosci Res. 2010 Dec;88(16):3588-97. doi: 10.1002/jnr.22503. Epub 2010 Oct 1.

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer's Disease.

ACS Chem Neurosci. 2018 Nov 21;9(11):2588-2598. doi: 10.1021/acschemneuro.8b00091. Epub 2018 Jun 7.

Alzheimer's drug update. Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.

Harv Mens Health Watch. 2013 Jan;17(6):6-7.

Quinazolinones as γ-secretase modulators.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):773-6. doi: 10.1016/j.bmcl.2010.11.111. Epub 2010 Nov 26.

Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.

Bioorg Med Chem Lett. 2012 May 1;22(9):3203-7. doi: 10.1016/j.bmcl.2012.03.038. Epub 2012 Mar 17.

[Therapy of Alzheimer disease].

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33.

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012).

Expert Opin Ther Pat. 2013 May;23(5):581-96. doi: 10.1517/13543776.2013.772983. Epub 2013 Feb 21.

引用本文的文献

Degradation of FA reduces Aβ neurotoxicity and Alzheimer-related phenotypes.

Mol Psychiatry. 2021 Oct;26(10):5578-5591. doi: 10.1038/s41380-020-00929-7. Epub 2020 Dec 16.

Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.

Front Neurosci. 2019 Jan 10;12:1017. doi: 10.3389/fnins.2018.01017. eCollection 2018.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Targeting nascent soluble Aβ42 for potential Alzheimer drug development.

作者信息

Zhang Mingming, Hausmann Laura, Song Weihong

出版信息

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.

DOI:10.1111/jnc.12156

PMID:23405973

Abstract

摘要

相似文献

Targeting nascent soluble Aβ42 for potential Alzheimer drug development.

J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13.

Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.

J Neurochem. 2013 May;125(3):465-72. doi: 10.1111/jnc.12125. Epub 2013 Jan 8.

Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?

J Alzheimers Dis. 2010;22(2):401-4. doi: 10.3233/JAD-2010-101548.

Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.

J Neurosci Res. 2010 Dec;88(16):3588-97. doi: 10.1002/jnr.22503. Epub 2010 Oct 1.

Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer's Disease.

ACS Chem Neurosci. 2018 Nov 21;9(11):2588-2598. doi: 10.1021/acschemneuro.8b00091. Epub 2018 Jun 7.

Alzheimer's drug update. Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.

Harv Mens Health Watch. 2013 Jan;17(6):6-7.

Quinazolinones as γ-secretase modulators.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):773-6. doi: 10.1016/j.bmcl.2010.11.111. Epub 2010 Nov 26.

Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.

Bioorg Med Chem Lett. 2012 May 1;22(9):3203-7. doi: 10.1016/j.bmcl.2012.03.038. Epub 2012 Mar 17.

[Therapy of Alzheimer disease].

Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33.

Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 - 2012).

Expert Opin Ther Pat. 2013 May;23(5):581-96. doi: 10.1517/13543776.2013.772983. Epub 2013 Feb 21.

引用本文的文献

Degradation of FA reduces Aβ neurotoxicity and Alzheimer-related phenotypes.

Mol Psychiatry. 2021 Oct;26(10):5578-5591. doi: 10.1038/s41380-020-00929-7. Epub 2020 Dec 16.

Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.

Front Neurosci. 2019 Jan 10;12:1017. doi: 10.3389/fnins.2018.01017. eCollection 2018.